Loading
Everything OnCo dates to 1951: 5 entries, 3 landmarks, 1 approval and 1 technology. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
5 dated entries in OnCo fall in 1951: 3 landmarks, 1 approval and 1 technology.
Of those, 5 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Hyperthyroidism and thyroid carcinoma (first radiopharmaceutical approval)
The history entries editors wrote on cancer records: the dated turning points of each disease.
Myeloproliferative neoplasms (PV, ET, myelofibrosis). Proposes that PV, ET, CML and myelofibrosis are related myeloproliferative disorders.
Polycythaemia vera (PV). PV, essential thrombocythaemia, myelofibrosis and CML proposed as related diseases of the marrow.
Essential thrombocythaemia (ET)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.